HOXB13: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: HOXB13

NCBI ID: G10481

HOXB13

HOXB13: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with estimates reaching over 21,000 new cases and 16,200 deaths in the United States alone in 2020. Despite advances in treatment, the survival rate for ovarian cancer remains relatively low, highlighting the need for new and effective therapies. The HOXB13 gene, located on chromosome 13, has been identified as a potential drug target and biomarker for ovarian cancer.

HOXB13 gene and its function

The HOXB13 gene is a member of the homeobox gene family, which is a family of transcription factors that regulate gene expression and development. The HOXB13 gene is responsible for the production of the protein HOXB13, which plays a critical role in cell growth and differentiation.

HOXB13 functions as a negative regulator of the NF-kappa pathway, which is a well-established mechanism for promoting cancer growth and development. The NF-kappa pathway is a complex signaling pathway that is activated by various factors, including tyrosine signaling, which results in the formation of transforming growth factors.

HOXB13 has been shown to regulate the activity of several NF-kappa signaling pathway proteins, including SMAD1, SMAD4, and NF-kappa1. By doing so, it can inhibit the effects of NF-kappa signaling and potentially contribute to the development and progression of ovarian cancer.

HOXB13 as a drug target

The HOXB13 gene has been identified as a potential drug target for ovarian cancer due to its involvement in the NF-kappa pathway. Several studies have shown that inhibiting the activity of HOXB13 may be an effective way to treat ovarian cancer.

One approach to inhibiting HOXB13 activity is through the use of small molecules, which can act as either agonists or antagonists. For example, a series of studies have shown that the inhibitor, U012658, can inhibit the activity of HOXB13 and lead to the growth arrest and apoptosis of ovarian cancer cells.

Another approach to inhibiting HOXB13 activity is through the use of anti-NF-kappa antibodies, such as R1018. These antibodies have been shown to specifically bind to HOXB13 and can inhibit its activity.

HOXB13 as a biomarker

In addition to its potential as a drug target, HOXB13 has also been identified as a potential biomarker for ovarian cancer. The HOXB13 gene has been shown to be expressed in ovarian cancer tissues and cell lines, and its expression has been associated with the poor prognosis of ovarian cancer.

Furthermore, some studies have shown that HOXB13 has been overexpressed in ovarian cancer tissues, which may indicate that it is a potential biomarker for the disease. Additionally, HOXB13 has been shown to be expressed in the blood vessels of ovarian cancer patients, which may indicate that it can be used as a potential marker for the disease.

Conclusion

HOXB13 is a gene that has been shown to play a critical role in the development and progression of ovarian cancer. Its function as a negative regulator of the NF-kappa pathway makes it an attractive target for drug development. Furthermore, its potential as a biomarker for ovarian cancer makes it an important addition to the diagnostic toolkit for this disease.

While further research is needed to fully understand the role of HOXB13 in ovarian cancer, its potential as a drug target and biomarker is a promising direction for future research. With further studies, scientists may uncover new ways to treat ovarian cancer and improve survival rates for this disease.

Protein Name: Homeobox B13

Functions: Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. Binds preferentially to methylated DNA (PubMed:28473536)

The "HOXB13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HOXB13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets